A public outcry has led to the NZ government’s drug funding agency making a partial backdown on a policy that restricted lamotrigine prescriptions to just one generic brand for people with epilepsy. The country’s drug buying agency Pharmac removed brands including Lamictal from public funding on 1 October and stipulated that patients could access the ...
Seizure deaths cause concern after lamotrigine generic switch
By Michael Woodhead
21 Nov 2019